| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Axsome Therapeutics, Inc. (AXSM) has 9 insiders with recent SEC Form 4 filings, including 18 buys and 0 sells. AXSM is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 57.5K | $13.53M | - | |
| Dir | 48.2K | $11.35M | - | |
| CEO | 24.1K | $5.67M | - | |
| COO | 8.7K | $2.04M | - | |
| CFO | 8.2K | $1.93M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 18, 2021 | Pizzie Nick50 | Chief Financial Officer | Buy | 955 | $35.26 | $33,676.03 | +2.3% | -11.2% | +57.8% | |
| Nov 18, 2021 | Coleman Mark | Director | Buy | 1,430 | $35.09 | $50,180.73 | +0.2% | -11.2% | +57.8% | |
| Nov 17, 2021 | Saad Mark E50 | Director | Buy | 3,300 | $34.52 | $113,921.70 | +47.1% | -2.3% | +54.2% | |
| May 12, 2021 | Coleman Mark | Director | Buy | 500 | $58.15 | $29,075.00 | +0.1% | -58.3% | -55.6% | |
| Jun 29, 2020 | Coleman Mark | Director | Buy | 650 | $78.50 | $51,025.00 | +0.2% | - | - | |
| Jun 29, 2020 | Pizzie Nick50 | Chief Financial Officer | Buy | 777 | $76.64 | $59,549.28 | +1.9% | - | - | |
| Sep 26, 2019 | Pizzie Nick50 | Chief Financial Officer | Buy | 2,180 | $24.80 | $54,064.00 | +5.7% | - | - | |
| Jun 26, 2019 | Coleman Mark | Director | Buy | 16,200 | $23.10 | $374,280.00 | +1.2% | - | - | |
| Jun 11, 2019 | Pizzie Nick50 | Chief Financial Officer | Buy | 1,920 | $20.80 | $39,936.00 | New | - | - | |
| May 23, 2019 | Saad Mark E50 | Director | Buy | 3,500 | $22.33 | $78,155.00 | +99.9% | - | - |